Kenneth Rose, MD
Internal Medicine · Muscle Shoals, ALNPI 1215921978
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 663 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,258 and has fallen 76.7% since, to $527 in 2025. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 663 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$809
- AstraZeneca$784
- Johnson & Johnson$593
- GSK$526
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,820100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 150 | $2,198 |
| Lilly USA, LLC | 97 | $1,211 |
| AbbVie(2 entities) | 85 | $809 |
| AstraZeneca | 22 | $784 |
| Johnson & Johnson | 37 | $593 |
| GSK | 34 | $526 |
| Pfizer | 34 | $434 |
| Amgen(2 entities) | 18 | $428 |
| Boehringer Ingelheim | 27 | $335 |
| Novartis | 19 | $326 |
| Amarin Pharma, Inc. | 21 | $299 |
| Astellas Pharma US Inc | 12 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $274 |
| Merck | 12 | $210 |
| Bayer | 11 | $174 |
| Ironwood Pharmaceuticals, Inc | 7 | $96 |
| Viiv Healthcare Company | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 6 | $75 |
| Genentech USA, Inc. | 4 | $66 |
| Dexcom, Inc. | 4 | $66 |
| Eisai Inc. | 5 | $62 |
| Bausch Health US, LLC | 4 | $52 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Melinta Therapeutics, LLC | 3 | $45 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Daiichi Sankyo Inc. | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Seqirus USA Inc | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Abbott | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$200
- INVOKANA$100
- TRELEGY ELLIPTA$100
- AIMOVIG$100
- Repatha$100
How this compares
$9,864 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $240,335 |
| EliquisApixaban | 687 | $240,042 |
| JardianceEmpagliflozin | 202 | $190,119 |
| MounjaroTirzepatide | 109 | $122,254 |
| FarxigaDapagliflozin Propanediol | 253 | $106,590 |
| XareltoRivaroxaban | 214 | $79,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $70,205 |
| JanuviaSitagliptin Phosphate | 122 | $61,964 |
| OtezlaApremilast | 11 | $53,280 |
| TrulicityDulaglutide | 30 | $49,136 |
| TradjentaLinagliptin | 100 | $40,469 |
| Invega SustennaPaliperidone Palmitate | 12 | $36,888 |
| Repatha SureclickEvolocumab | 55 | $32,011 |
| NuplazidPimavanserin Tartrate | 24 | $29,516 |
| RybelsusSemaglutide | 15 | $17,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,198 | $257,663217 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $335 | $247,557320 claims |
| PfizerEliquis | $434 | $240,042687 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,211 | $171,390139 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $593 | $116,017226 claims |
| AstraZenecaFarxiga | $784 | $106,590253 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $526 | $80,684116 claims |
| MerckJanuvia | $210 | $61,964122 claims |
| AmgenOtezla | $428 | $53,28011 claims |
| Astellas Pharma US IncMyrbetriq | $277 | $16,46133 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $40 | $16,18620 claims |
| AbbVieLinzess | $809 | $15,54127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Muscle Shoals
- Loren McCoyMuscle Shoals$48K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.